Anastrozole Halves Breast Cancer Incidence in High-Risk Postmenopausal Women (FREE)

By Amy Orciari Herman The aromatase inhibitor anastrozole cuts breast cancer incidence in half among high-risk postmenopausal women, according to an industry-supported trial in the Lancet.Nearly 4000 postmenopausal women at increased risk (e.g., …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news